Raw Selpercatinib Powder

Name: China Raw Selpercatinib Powder Suppliers, Manufacturers - Factory Direct Price - Jianfeng Chemical
Brand: Jianfeng
SKU: 210888679

CAS:2152628-33-4
MF:C29H31N7O3
MW:525.6
Shipping:The same day shipping
Payment:T/T,Paypal,Western union.......
Puirty: 99%
MOQ:1KG

Send Inquiry

Description

CPD2206;LOX-292;LOXO-292;LOXO292;LOXO292;LOXO-292,Selpercatinib;Selpercatinib(LOXO-292);6-?(2-?Hydroxy-?2-?methylpropoxy)?-?4-?[6-?[6-?[(6-?methoxy-?3-?pyridinyl)?methyl]?-?3,?6-?diazabicyclo[3.1.1]?hept-?3-?yl]?-?3-?pyridinyl]?pyrazolo[1,?5Chemicalbook-?a]?pyridine-?3-?carbonitrile;Pyrazolo[1,5-a]pyridine-3-carbonitrile,6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-;LOXO-292USP/EP/BP

CAS number: 2152628-33-4

Molecular formula: C29H31N7O3

Molecular weight: 525.6

Tel: 8615628852771

Whatsapp: 8615628852771

Email: sales09@pharmachemm.com

Web:

www.pharmachemm.com

www.jianfengchemical.com

FAX:0086-531-88113608

product-490-486

Selpercatinib, also known by its brand name Retevmo, is a targeted therapy medication used in the treatment of certain types of cancers. It specifically targets and inhibits the abnormal activity of a gene called RET, which can be mutated and drive the growth of cancer cells. Selpercatinib is mainly used for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other solid tumors with RET gene fusions or mutations. As a targeted therapy, it aims to block the action of the RET protein and potentially slow down or stop the growth of cancer cells. However, like any medication, it may have side effects and should be used under medical supervision.

Density: 1.36±0.1g/cm3(Predicted)

Storage conditions: Storeat-20°C

Solubility: DMSO: 20.0(MaxConc.mg/mL); 38.05(MaxConc.mM)

Form: Acrystallinesolid

Acidity system (pKa):

14.00±0.29(Predicted)InChIInChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24) 20-5-6-2Chemicalbook6(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11- 19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

InChIKey: XIIOFHFUYBLOLW-UHFFFAOYSA-N

SMILES: C12=C(C#N)C=NN1C=C(OCC(O)(C)C)C=C2C1=CC=C(N2CC3CC(N3CC3=CC=C(OC)N=C3)C2)N =C1

product-730-730

Introduction:

Saracatinib (AZD0530) is an oral small molecule Src inhibitor developed by AstraZeneca. AZD0530 is a quinazoline derivative with aniline substitution at the 4-position, so it also has EGFR tyrosine kinase inhibitor activity, but the inhibitory activity is mediocre. AZD0530 has a strong ability to penetrate the blood-brain barrier. AZD0530 may reverse P-glycoprotein-mediated tumor multidrug resistance. AZD0530 has the effect of increasing bone density and relieving pain in the treatment of bone metastasis of malignant tumors.

effect:

Saracatinib is a potent Src inhibitor with IC50 of 2.7nM, also effective on c-Yes, Fyn, Lyn, Blk, Fgr and Lck; slightly less active on Abl and ChemicalbookEGFR (L858R and L861Q). Saracatinib is the first inhibitor of the Src pathway in human tumor tissue.

Biological activity:

Selpercatinib (LOXO-292, ARRY-192) is an effective and specific RET (c-RET) inhibitor for WTRET (c-RET), RET (c-RET) (V804M), RET (c-RET) (V804L), RET(c-RET)(A883F), RET(c-RET)(M918T) and RET(c-RET)(S891A) have IC50 values of 1nM, 2nM, 2nM, 4nM, 2nM and 2nM, respectively.